Asa Biopharm's Podcast

Freda and Ed discuss what to expect at the 2016 Biopharm Workshop

Marisa Bacchi discusses the first EFSPI workshop on regulatory statistics.

Marie Davidian, Montse Fuentes & Mladen Vouk define data science, discuss related ASA initiatives and describe the data science program at NC State.

Donna LaLonde, Dalene Stangl & Jiayang Sun discuss the origins and program for the upcoming WSDS conference.

Alan Hartford and Matt Rotelli discuss the mission of the group and the importance of communication between statisticians and pharmacometricians.

Nancy Flournoy, Ji-Hyun Lee, Paula Roberson and Jiayang Sun discuss the goals and activities of the caucus.

Veronica discusses the Center for Veterinary Medicine at FDA.

Michael Hale, Jonathan Hartzel, Sara Hughes, Ted Lystig & Estelle Russek-Cohen discuss the implications of data transparency for the pharmaceutical industry.

Greg Campbell discusses his career at the FDA and shares his thoughts on the future of medical product development.

Amit Bhattacharyya, Jie Chen, Frank Fan & Yang Song discuss the mission of the ISBS and the regulatory environment in China.

Wei and Richard discuss the 2015 ASA Biopharmaceutical Section Statistics Workshop. Rima Izem conducts the interview.

Qi and Olga discuss the first scientific working group of the ASA Biopharmaceutical Section.

As current Chair for the Biopharmaceutical Section, Dionne discusses her goals for the upcoming year.

Chrissie Fletcher discusses EFSPI, the European Federation of Statisticians in the Pharmaceutical Industry.

Zoran Antonijevic discusses the DIA Scientific Working Group on Adaptive Designs, and the upcoming Joint Adaptive Design and Bayesian Statistics Conference in Feb 2015.

Amarjot Kaur discusses the new mentoring program of the ASA Biopharmaceutical Section.

A recording of A Conversation with Bob O'Neill which took place during a recent ASA Boston Chapter meeting. Dr. O’Neill discusses aspects of the past, present, and future of regulatory statistics in an interview format with Dr. Scott Evans. Topics include: Dr. O’Neill’s view of challenging issues of the future, key challenges for the FDA during his tenure, and training in regulatory statistics and decision making.

Ted Lystig discusses some of the unique challenges present in the development of medical devices, and the recent formation of the new ASA Section on Medical Devices and Diagnostics.

Cristiana and Shiowjen discuss the 2014 ASA Biopharm Section FDA-Industry Statistics Workshop.

Ivan Chan discusses Biopharm Section activities at the 2014 Joint Statistical Meetings in Boston.